Preclinical study of CC223 as a potential anti-ovarian cancer agent

Aberrant activation of mTOR contributes to ovarian cancer progression. CC223 is a novel and potent mTOR kinase inhibitor. The current study tested its activity against human ovarian cancer cells. We showed that CC223, at nM concentrations, inhibited survival and proliferation of established/primary...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Zhenzhen, Niu, Huanfu, Wang, Xuenan, Zhang, Lei, Wang, Qin, Yang, Aijun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601667/
https://www.ncbi.nlm.nih.gov/pubmed/28938571
http://dx.doi.org/10.18632/oncotarget.17753

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601667/
https://www.ncbi.nlm.nih.gov/pubmed/28938571
http://dx.doi.org/10.18632/oncotarget.17753

Ejemplares similares